TY - JOUR
T1 - Somatostatin Receptor PET/CT Imaging for the Detection and Staging of Pancreatic NET
T2 - A Systematic Review and Meta-Analysis
AU - Bauckneht, Matteo
AU - Albano, Domenico
AU - Annunziata, Salvatore
AU - Santo, Giulia
AU - Guglielmo, Priscilla
AU - Frantellizzi, Viviana
AU - Branca, Alessia
AU - Ferrari, Cristina
AU - Vento, Antonio
AU - Mirabile, Alessia
AU - Nappi, Anna Giulia
AU - Evangelista, Laura
AU - Alongi, Pierpaolo
AU - Laudicella, Riccardo
N1 - Funding Information:
This research received no external funding.
Publisher Copyright:
© 2020 by the authors.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/8
Y1 - 2020/8
N2 - We investigated the diagnostic performance of Somatostatin Receptor Positron Emission Tomography/Computed Tomography (SSR-PET/CT) for the detection of primary lesion and initial staging of pancreatic neuroendocrine tumors (pNETs). A comprehensive literature search up to January 2020 was performed selecting studies in presence of: sample size ≥10 patients; index test (i.e., 68Ga-DOTATOC or 68Ga-DOTANOC or 68Ga-DOTATATE PET/CT); and outcomes (i.e., detection rate (DR), true positive, true negative, false positive, and false-negative). The methodological quality was evaluated with QUADAS-2. Pooled DR and pooled sensitivity and specificity for the identification of the primary tumor were assessed by a patient-based and a lesion-based analysis. Thirty-eight studies were selected for the qualitative analysis, while 18 papers were included in the meta-analysis. The number of pNET patients ranged from 10 to 142, for a total of 1143 subjects. At patient-based analysis, the pooled sensitivity and specificity for the assessment of primary pNET were 79.6% (95% confidence interval (95%CI): 71–87%) and 95% (95%CI: 75–100%) with a heterogeneity of 59.6% and 51.5%, respectively. Pooled DR for the primary lesion was 81% (95%CI: 65–90%) and 92% (95%CI: 80–97%), respectively, at patient-based and lesion-based analysis. In conclusion, SSR-PET/CT has high DR and diagnostic performances for primary lesion and initial staging of pNETs.
AB - We investigated the diagnostic performance of Somatostatin Receptor Positron Emission Tomography/Computed Tomography (SSR-PET/CT) for the detection of primary lesion and initial staging of pancreatic neuroendocrine tumors (pNETs). A comprehensive literature search up to January 2020 was performed selecting studies in presence of: sample size ≥10 patients; index test (i.e., 68Ga-DOTATOC or 68Ga-DOTANOC or 68Ga-DOTATATE PET/CT); and outcomes (i.e., detection rate (DR), true positive, true negative, false positive, and false-negative). The methodological quality was evaluated with QUADAS-2. Pooled DR and pooled sensitivity and specificity for the identification of the primary tumor were assessed by a patient-based and a lesion-based analysis. Thirty-eight studies were selected for the qualitative analysis, while 18 papers were included in the meta-analysis. The number of pNET patients ranged from 10 to 142, for a total of 1143 subjects. At patient-based analysis, the pooled sensitivity and specificity for the assessment of primary pNET were 79.6% (95% confidence interval (95%CI): 71–87%) and 95% (95%CI: 75–100%) with a heterogeneity of 59.6% and 51.5%, respectively. Pooled DR for the primary lesion was 81% (95%CI: 65–90%) and 92% (95%CI: 80–97%), respectively, at patient-based and lesion-based analysis. In conclusion, SSR-PET/CT has high DR and diagnostic performances for primary lesion and initial staging of pNETs.
KW - Neuroendocrine tumors
KW - Pancreas
KW - Positron emission tomography
KW - Somatostatin receptor analogs
UR - http://www.scopus.com/inward/record.url?scp=85090361169&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090361169&partnerID=8YFLogxK
U2 - 10.3390/diagnostics10080598
DO - 10.3390/diagnostics10080598
M3 - Review article
AN - SCOPUS:85090361169
VL - 10
JO - Diagnostics
JF - Diagnostics
SN - 2075-4418
IS - 8
M1 - 598
ER -